EFG Asset Management’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
$5.82M Sell
79,436
-25,003
-24% -$1.66M 0.75% 34
2025
Q2
$5.43M Buy
104,439
+1,347
+1% +$76.6K 0.77% 39
2025
Q1
$6.57M Sell
103,092
-25,202
-20% -$1.46M 1.09% 14
2024
Q4
$6.13M Buy
128,294
+19,881
+18% +$1.02M 0.84% 25
2024
Q3
$6.2M Sell
108,413
-31,856
-23% -$1.83M 1.04% 13
2024
Q2
$7.35M Buy
140,269
+180
+0.1% +$7.89K 1.27% 11
2024
Q1
$5.69M Buy
140,089
+9,357
+7% +$351K 0.98% 17
2023
Q4
$4.83M Sell
130,732
-7,007
-5% -$264K 0.92% 20
2023
Q3
$5.26M Sell
137,739
-3,842
-3% -$157K 1.25% 14
2023
Q2
$5.11M Buy
141,581
+26,111
+23% +$891K 1.1% 19
2023
Q1
$4.41M Sell
115,470
-9,102
-7% -$427K 0.97% 35
2022
Q4
$7.1M Sell
124,572
-26,183
-17% -$1.34M 1.59% 5
2022
Q3
$5.96M Sell
150,755
-21,214
-12% -$938K 1.38% 13
2022
Q2
$7.57M Sell
171,969
-122,444
-42% -$5.3M 1.59% 7
2022
Q1
$11.7M Sell
294,413
-1,243
-0.4% -$44.3K 1.76% 5
2021
Q4
$11.9M Buy
+295,656
New +$11M 1.55% 13

Other funds holding HALO

EFG Asset Management's HALO Position: Q3 2025 in Review

EFG Asset Management reduced its Halozyme (HALO) stake by 24% in Q3 2025, selling an estimated $1.66M and leaving 79,436 shares worth $5.82M. The position accounts for 0.75% of the portfolio, ranked #34.

EFG Asset Management first reported a position in HALO in Q4 2021 and has held it in 16 quarters since. The position peaked at $11.9M in Q4 2021. 602 funds tracked by Wall St. Rank hold HALO as of Q3 2025.

  • EFG Asset Management held 79,436 shares of Halozyme worth $5.82M as of Q3 2025.
  • EFG Asset Management sold 25,003 Halozyme shares in Q3 2025, an estimated $1.66M.
  • Halozyme made up 0.75% of EFG Asset Management's portfolio in Q3 2025, its #34 holding.
  • EFG Asset Management first reported a position in Halozyme in Q4 2021 and has held it in 16 quarters since.
  • EFG Asset Management's Halozyme position peaked at $11.9M in Q4 2021.
  • 602 funds tracked by Wall St. Rank held Halozyme as of Q3 2025.

Based on EFG Asset Management's 13F filing for Q3 2025, filed 3 Nov 2025.